Please login to the form below

Not currently logged in
Email:
Password:

lacosamide

This page shows the latest lacosamide news and features for those working in and with pharma, biotech and healthcare.

UCB bags FDA approval for epilepsy drug Briviact

UCB bags FDA approval for epilepsy drug Briviact

Belgium-headquartered UCB is already an established player in epilepsy with drugs such as Vimpat (lacosamide) and Keppra (levetiracetam), which is off-patent in most major markets.

Latest news

More from news
Approximately 4 fully matching, plus 16 partially matching documents found.

Latest Intelligence

  • VIDEO interview: Neil Weir, UCB VIDEO interview: Neil Weir, UCB

    For UCB, this notion is especially important considering its focus on severe diseases, including the recent launches of Cimzia (certolizumab pegol) for rheumatoid arthritis and Crohn's disease; Vimpat (lacosamide) for

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

MAT offers an information exchange called Rapid Payer Response that allows healthcare stakeholders to secure immediate, global, expert insight and...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics